Allogene Therapeutics Awarded $15M Grant From California Institute For Regenerative Medicine To Advance Development Of Allogeneic CAR T In Renal Cell Carcinoma
Allogene Therapeutics Awarded $15M Grant From California Institute For Regenerative Medicine To Advance Development Of Allogeneic CAR T In Renal Cell Carcinoma
Allogene Therapeutics獲得了加州再生醫學研究所的1500萬美元撥款，用於推進腎細胞癌異體CAR T的開發
- $15 million CIRM Grant Supports the Ongoing Phase 1 TRAVERSE Trial Evaluating ALLO-316 in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
- ALLO-316 Illustrates Proof-of-Concept in RCC and the Potential of Dagger Technology to Optimize CAR T Cell Expansion and Persistence
- 1500 萬美元 CIRM 撥款支持正在進行的評估 ALLO-316 晚期或轉移性腎細胞癌 (RCC) 患者的 1 期 TRAVERSE 試驗
- ALLO-316 說明了 RCC 中的概念驗證以及 Dagger 技術優化 CAR T 細胞擴展和持久性的潛力